Year All202620252024202320222021202020192018201720162014201320112010 February 8, 2022 Rhythm Pharmaceuticals to Host Virtual Bardet-Biedl Syndrome (BBS) Event on February 16 January 13, 2022 Rhythm Pharmaceuticals Announces First Patients Dosed in DAYBREAK and Weekly Trials Evaluating Setmelanotide for Rare Genetic Diseases of Obesity December 6, 2021 Rhythm Pharmaceuticals and RareStone Ltd. Announce Exclusive Licensing Agreement for the Development and Commercialization of IMCIVREE (setmelanotide) in China November 15, 2021 Rhythm Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome November 9, 2021 Rhythm Pharmaceuticals to Present at Stifel 2021 Virtual Healthcare Conference November 2, 2021 Rhythm Pharmaceuticals Reports Third Quarter 2021 Financial Results November 1, 2021 Rhythm Pharmaceuticals Presents First-ever Data Showing Improvements in Health-related Quality of Life for Patients Living with Bardet-Biedl Syndrome at ObesityWeek® 2021 October 20, 2021 Rhythm Pharmaceuticals to Report Third Quarter 2021 Financial Results on Tuesday, November 2, 2021 October 14, 2021 Rhythm Pharmaceuticals Completes Submission of Type II Variation Application to the European Medicines Agency for IMCIVREE® (setmelanotide) for Bardet-Biedl and Alström Syndromes October 14, 2021 Rhythm Pharmaceuticals Presents New Data on Experience of People Living with Rare Genetic Diseases of Obesity and Provides Updates on Uncovering Rare Obesity® Genetic Testing Program
February 8, 2022 Rhythm Pharmaceuticals to Host Virtual Bardet-Biedl Syndrome (BBS) Event on February 16
January 13, 2022 Rhythm Pharmaceuticals Announces First Patients Dosed in DAYBREAK and Weekly Trials Evaluating Setmelanotide for Rare Genetic Diseases of Obesity
December 6, 2021 Rhythm Pharmaceuticals and RareStone Ltd. Announce Exclusive Licensing Agreement for the Development and Commercialization of IMCIVREE (setmelanotide) in China
November 15, 2021 Rhythm Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome
November 1, 2021 Rhythm Pharmaceuticals Presents First-ever Data Showing Improvements in Health-related Quality of Life for Patients Living with Bardet-Biedl Syndrome at ObesityWeek® 2021
October 20, 2021 Rhythm Pharmaceuticals to Report Third Quarter 2021 Financial Results on Tuesday, November 2, 2021
October 14, 2021 Rhythm Pharmaceuticals Completes Submission of Type II Variation Application to the European Medicines Agency for IMCIVREE® (setmelanotide) for Bardet-Biedl and Alström Syndromes
October 14, 2021 Rhythm Pharmaceuticals Presents New Data on Experience of People Living with Rare Genetic Diseases of Obesity and Provides Updates on Uncovering Rare Obesity® Genetic Testing Program
